echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Science: Isolating SARS-CoV-2 neutralizing antibodies protects animals from virus attacks

    Science: Isolating SARS-CoV-2 neutralizing antibodies protects animals from virus attacks

    • Last Update: 2020-07-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The devastating effects of neo-coronapneumonia (COVID-19) on global health continue to persist, and there is no cure or a vaccineObtaining neutralizing antibodies (nAbs) in the pathogen of the new coronavirus (SARS-CoV-2) may be a potential prevention and treatment option that can also help guide vaccine designOn June 15,, the team from the Scripps Institution of The United States published the latest findings in Science of SARS-CoV-2 neutralizing antibodies, separating two episomen on the receptor-binding domain (RBD) and effective neutralizing antibodies (nAbs) on different non-RBD episomenins (S) and finding that the use of nAbs could protect Syrian silos exposed to high doses of SARS-CoV-2 attacksSpecifically, the researchers recruited 17 patients in California who had been infected with SARS-CoV-2 and collected peripheral blood mononucleocells (PBMC) and plasmaAt the same time, heLa-ACE2 cell lines, which produce powerful and repeatable virus titrons, were developed, and the binding of donor plasma and recombinant SARS-CoV-2 S-proteinand receptor-binding domain (RBD) proteins were tested using pseudo-virus (PSV) neutralization methodsfound that the binding price of donor plasma and SARS-CoV-2 S protein varied greatly, but the effect price of RBD was reduced by an order of magnitudeThe researchers then identified monoclonal antibodies (mAb) on eight of the donors, cloned and expressed 2,045 antibodies, and tested their binding to RBD and S proteins, as well as neutralizing SARS-CoV-2 PSV assaysresults were unexpected, and the viral infection responded more strongly to the non-RBD regions of the S protein, but only a small portion was neutralizedIn contrast, RBD binds fewer antibodies, but neutralises a higher proportion of SARS-CoV-2 pseudo-virusesThe researchers then used the S-protein and RBD protein as antibodies that were used to capture antigen detection binding to non-competitive sites, and found three antigen-determining cluster spools (RBD-A, RBD-B, and RBD-C) and S proteins (SA, SB, and SC), they continued to evaluate the neutrality of monoclonal antibodies against SARS-CoV-2 and SARS-CoV-1 counterfeit virusesThe results showed that the most effective neutralizing antibodies were antibodies against RBD-A epitopes, including two antibodies CC6.29 and CC6.30, which were efficient in neutralizing SARS-CoV-2 pseudoviruses, while CC6.33 was for RBD-B, which neutralized both SARS-CoV-2 and SARS-CoV-1through cell surface competitive experiments and surface plasma resonance (SPR) experiments, the researchers determined that the epitope RBD-A is the preferred target for neutralizing antibodies, and that the corresponding increase in the affinity of mAb and RBD-A may lead to a corresponding increase in neutrality forceIt is worth noting that all three antibodies can neutralise the now mutated SARS-CoV-2 virusTo study the protection of SARS-CoV-2 in vitro neutralizing antibodies, the researchers screened two mAb-processed Syrian hamster animal modelsThe hamster was weighed as a measure of disease caused by infection using the non-existing antibody Den3 of the dengue virus as a control results showed that in CC12.1 and targeted RBD-A epitope treatment, the control group lost an average weight of 13.6%, while the experimental group receiving neutral RBD-A antibodies at a dose of 2 mg or 500 mg was not weight loss, and the lung virus load was further verified by using real-time PCR to determine its lung virus load The researchers measured the serum concentration of antibodies before the Attack of the Syrian hamster nasal virus and found that the antibody serum concentration was about 22 ?g/ml of nAb, which was sufficient to reduce the disease caused by a 50% weight loss at a serum concentration of 12 ?g/ml However, the concentration of effective antibodies required to prevent disease at the site of infection has yet to be determined summary, the study showed that nAb plays a role in the prevention and potential treatment of COVID-19 At the same time, nAb also defines protective tables that can be used to guide vaccine design notable, in addition to the study, Science published four other studies on the same day on antibodies to the new coronavirus, including human-sourceed antibodies and antibody "cocktail therapy." Previously, the results of neutralizing antibodies in the new coronavirus have also been frequently published We look forward to these findings as soon as possible to promote clinical application development and provide a strong medical intervention for the treatment and prevention of new coronary pneumonia
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.